CytomX Therapeutics, a clinical-stage biopharmaceutical company based in South San Francisco, develops conditionally activated biologics for oncology, with a pipeline including CX-904 and CX-2051. The company went public on October 8, 2015, and has 120 employees.
CTMX filed a patent for "masking polypeptides, activatable cytokine constructs, and related compositions and methods" on Wed, April 12, 2023.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
